Beijing: China has given conditional approval for a single dose COVID-19 vaccine, touted to be a rival to Johnson & Johnson’s one-jab shot cleared by the US drug regulator on Sunday.
China's first Ad5-nCoV COVID-19 vaccine was rolled out on Friday, the state-run Global Times reported on Sunday.
Phase-I clinical trials of the vaccine started on March 16, last year, making it the world's first COVID-19 candidate vaccine that entered clinical trials, it said.
It is the only single-dose COVID-19 vaccine that has been given conditional approval to be rolled out in China, the report quoted last Friday’s story by the state broadcaster China Central Television (CCTV).
People can get desirable protective effect after 14 days of inoculation.
The protective effect can last at least six months after a single-dose inoculation and it can increase immune response by 10 to 20 times if the second dose is taken half a year after the first one, the report said.
With this, China’s medical products regulator has approved five coronavirus vaccines which include Sinovac, Sinopharm, CanSinoBio and another by Wuhan Institute of Biological Products.
One of the developers of the Ad5-nCoV vaccine said that the annual production capacity can reach 500 million doses, which means 500 million people can be vaccinated in a year.
Phase-I clinical trials of the vaccine started on March 16, 2020, making it the world's first COVID-19 candidate vaccine that entered clinical trials, the Global Times report said.
Though China has been supplying its vaccines to different countries, none of them have been approved by the World Health Organisation (WHO).
The Ad5-nCoV vaccine is a recombinant adenovirus vector vaccine jointly developed by CanSino Biologics and researchers from the Institute of Military Medicine under the Academy of Military Sciences led by Chen Wei, who is an infectious disease expert and a researcher at the Institute of Military Medicine under the Academy of Military Sciences.
"We have data for six months so far to prove the vaccine's efficacy. People don't need to take another dose within the first six months after their first inoculation. What if the epidemic is not over after six months? We have also developed the vaccine so that its effect is strengthened even after six months," Chen said.
The US Food and Drug Administration on Saturday approved Johnson and Johnson's COVID-19 vaccine, the third jab to be authorised to fight the pandemic that has claimed over half a million lives in the country.
The vaccine is set to be a cost-effective alternative to the Pfizer and Moderna vaccines, and can be stored in a refrigerator instead of a freezer.
Trials found it prevented serious illness but was 66 per cent effective overall when moderate cases were included. The vaccine is made by the Belgian firm Janssen.
China has been stepping up coronavirus vaccine production as it looks to vaccinate its 1.4 billion population and boost its vaccine diplomacy to make strategic gains.
Last Friday, China welcomed India supplying more COVID-19 vaccines to a number of countries, playing down reports that New Delhi has beaten Beijing in its vaccine diplomacy around the world.
Responding to a question on a report that India has beaten China at its own game of vaccine diplomacy, Chinese Foreign Ministry spokesman Wang Wenbin during a media briefing said, “We welcome that and hope to see more countries taking actions to provide vaccines to the world, especially developing countries, to help with the global response."
"China has been overcoming domestic difficulties to provide vaccines to other countries in concrete measure," he said, flagging China’s own vaccine requirement to inoculate its 1.4 billion population.
He reiterated that China has been providing vaccines to 53 countries and exporting vaccines to 27 countries, amid reports that many of those countries are yet to receive Chinese vaccines or the promised quantities.
This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.
Subscribe to Mint Newsletters * Enter a valid email * Thank you for subscribing to our newsletter.
Share Via
Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.
Una posible portadora de la COVID-19 es revisada por equipo médico en Wuhan.

La vacuna monodosis, desarrolada por un grupo de investigación dirigido por la académica y epidiemologa china , ha sido recientemente aprobada condicionalmente por la Administración Nacional de Productos Médicos de , país que ya contiene 3 vacunas aprobadas en su territorio. Por el momento solo se habían autorizado el uso de dos vacunas, en modo de emergencia: la dosis  de la farmaceútcia , la de vacuna  de , así como la aprobación de la vacuna  de la empresa china .

Se prevé su uso solamente a personas mayores de 18 años, asimismo, la vacuna puede almacenarse y transportarse si se mantiene en una temperatura de 2 y 8 grados centígrados.

Según medios locales chinos, los estudios premilinares afirman que tiene un 65,7% de efectividad en casos con síntomas visibles y un 90,98% de efectividad en casos graves.

La fase inicial de pruebas clínicas de la vacuna iniciará el 16 de marzo, y se convierte en la primera inmunización creada en China que requiere una aplicación de una única dosis. Según las características que presentaron en el informe, la vacuna crea anticuerpos tras 14 días de inoculación, tiene efecto protector con una duración máxima de 6 meses tras la primera inmunización aplicada, y la respuesta inmunitaria puede aumentar de 10 a 20 veces si se suministra una segunda dosis después de medio año de aplicada la primera.